Generics Favored In Sweeping French Reforms

20 November 1995

Generic drugs will be given priority in the French health service and tougher controls will ensure patients get the treatments they need and no more. Those were two of the messages delivered to the National Assembly by the Prime Minister, Alain Juppe, in an address winding up two days of debate on social security and health service cost containment.

Mr Juppe said that under the arrangements for generics, pharmacists would have the opportunity to deliver "precisely the quantity of drugs necessary for treatment," as was already the case, for example, in the UK. This would avoid the sort of over-prescribing of large packs of drugs which ended up scarcely used, were reimbursed by the French social security system and ended in the incinerator.

Opening his comments, Mr Juppe said it is the government's commitment to improve the quality of health care. A national health spending limit will be fixed for 1996 and this will be strictly linked to the price index. Economies amounting to about 5 billion French francs ($1.02 billion) have also been called for by the Prime Minister from both the doctors and the drug industry, a measure described by Mr Juppe as "efforts of solidarity."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight